,5 Next-generation EGFR and ALK inhibitors and ROS1, RET, MET, and NTRK inhibitors that penetrate the blood-brain barrier were found to have promising activity against BM in patients with NSCLC whose primary tumors carry mutations in these genes.6 This evidence concerns the gene ALK and non-small cell lung carcinoma.